View in EDS HTML Full Text PDF Full Text

Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia.
Authors: Küchler S; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany., Brilloff S; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany., Schäfer S; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany., Rahimian E; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany., Kufrin V; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany., Peri SS; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany., Musa J; Department of General, Visceral, Thoracic, and Transplant Surgery, University Hospital of Giessen and Marburg, Giessen, Germany.; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany., Grünewald TGP; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.; Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Schewe DM; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany., Ball CR; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany.; TU Dresden University of Technology, Faculty of Biology, Dresden, Germany., Bornhäuser M; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany., Glimm H; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany.; Translational Functional Cancer Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bill M; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.; German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany., Wurm AA; Mildred Scheel Early Career Center, National Center for Tumor Diseases (NCT/UCC) Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany. alexander.wurm@nct-dresden.de.; Department for Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, and Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany. alexander.wurm@nct-dresden.de.; Department of Pediatric Hematology and Oncology, University Hospital Dresden and National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany. alexander.wurm@nct-dresden.de.; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany. alexander.wurm@nct-dresden.de.; German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany. alexander.wurm@nct-dresden.de.
Source: Cell death discovery [Cell Death Discov] 2025 Oct 20; Vol. 11 (1), pp. 470. Date of Electronic Publication: 2025 Oct 20.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 101665035 Publication Model: Electronic Cited Medium: Print ISSN: 2058-7716 (Print) Linking ISSN: 20587716 NLM ISO Abbreviation: Cell Death Discov Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2058-7716
DOI:10.1038/s41420-025-02810-4